UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Impact of Brain Metastases on Treatment Patterns and Outcomes With First-Line Durvalumab Plus Platinum-Etoposide in Extensive-Stage SCLC (CASPIAN): A Brief Report

JTO clinical and research reports, 2022-06, Vol.3 (6), p.100330-100330, Article 100330

2022

Volltextzugriff (PDF)

Overall survival in patients with metastatic renal cell carcinoma in Russia, Kazakhstan, and Belarus: a report from the RENSUR3 registry

Cancer reports, 2021-06, Vol.4 (3), p.e1331-n/a

2021

Volltextzugriff (PDF)

Clinical case of long-term use of durvalumab in the treatment of advanced small-cell lung cancer

Sovremennaia onkologiia : zhurnal kafedry onkologii RMAPO dlia nepreryvnogo poslediplomnogo obrazovaniia, 2020-07, Vol.22 (2), p.112-115

2020

Volltextzugriff (PDF)

A phase Ib study of alofanib, an allosteric FGFR2 inhibitor, in patients with advanced or metastatic gastric cancer

Journal of clinical oncology, 2020-02, Vol.38 (4_suppl), p.TPS466-TPS466

2020

Volltextzugriff (PDF)

The association of access to systemic therapy and overall survival in metastatic bladder cancer in Russia: An analysis of URRU register

Journal of clinical oncology, 2021-10, Vol.39 (28_suppl), p.88-88

2021

Volltextzugriff (PDF)

Durvalumab ± Tremelimumab + Platinum-Etoposide in Extensive-Stage Small Cell Lung Cancer (CASPIAN): Outcomes by PD-L1 Expression and Tissue Tumor Mutational Burden

Clinical cancer research, 2024-02, Vol.30 (4), p.824-835

2024

Volltextzugriff (PDF)

Alofanib in subsequent therapy for advanced gastric cancer: Final results from the phase Ib clinical trial

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.e16077-e16077

2022

Volltextzugriff (PDF)

Patient-reported outcomes with first-line durvalumab plus platinum-etoposide versus platinum-etoposide in extensive-stage small-cell lung cancer (CASPIAN): a randomized, controlled, open-label, phase III study

Lung cancer (Amsterdam, Netherlands), 2020-11, Vol.149, p.46-52

2020

Volltextzugriff (PDF)

A first-in-human phase 1b study of a novel allosteric extracellular FGFR2 inhibitor alofanib in patients with refractory metastatic gastric cancer

Journal of clinical oncology, 2022-02, Vol.40 (4_suppl), p.304-304

2022

Volltextzugriff (PDF)

A phase 1b study of the allosteric extracellular FGFR2 inhibitor alofanib in patients with pretreated advanced gastric cancer

Investigational new drugs, 2023-04, Vol.41 (2), p.324-332

2023

Volltextzugriff (PDF)

Abstract CT113: Preliminary data on a phase 1b, first-in-human study of the allosteric extracellular FGFR2 inhibitor alofanib in patients with refractory metastatic gastric cancer

Cancer research (Chicago, Ill.), 2021-07, Vol.81 (13_Supplement), p.CT113-CT113

2021

Volltextzugriff (PDF)

O11-5 Durvalumab(D) ± tremelimumab(T) + platinum-etoposide(EP) in 1L ES-SCLC: Characterization of long-term benefit in CASPIAN

Annals of oncology, 2021-07, Vol.32, p.S289-S289

2021

Volltextzugriff (PDF)

Elderly patients have limited access to systemic therapy for metastatic renal cell carcinoma (mRCC) and shorter overall survival in Russia, Belarus and Kazakhstan

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.e23033-e23033

2019

Volltextzugriff (PDF)

First-line durvalumab plus platinum-etoposide in extensive-stage (ES)-SCLC (CASPIAN): Impact of brain metastases on treatment patterns and outcomes

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.9068-9068

2020

Volltextzugriff (PDF)

Durvalumab ± tremelimumab + platinum-etoposide in first-line extensive-stage SCLC (ES-SCLC): Updated results from the phase III CASPIAN study

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.9002-9002

2020

Volltextzugriff (PDF)

Five-year Survival of Patients With Metastatic Renal Cell Carcinoma in the Russian Federation: Results From the RENSUR5 Registry

Clinical genitourinary cancer, 2017-12, Vol.15 (6), p.e1069-e1072

2017

Volltextzugriff (PDF)

Five-year overall survival among patients with metastatic renal cell carcinoma: Results of Russian population-based study RENSUR5

Journal of clinical oncology, 2017-02, Vol.35 (5_suppl), p.20-20

2017

Volltextzugriff (PDF)

Non-interventional study OVATAR final report: Diagnostic and treatment approaches in Russian ovarian cancer population—BRCAm group analysis

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.e13111-e13111

2019

Volltextzugriff (PDF)

Interim analysis of the data of non-interventional study to determine the prevalence of EGFR mutations in advanced NSCLC Russian patients (ORTUS)

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.e13109-e13109

2019

Volltextzugriff (PDF)

Comprehensive analysis of germline and somatic BRCA1/2 mutations in ovarian cancer population: Interim results of OVATAR prospective study

Journal of clinical oncology, 2017-05, Vol.35 (15_suppl), p.e23109-e23109

2017

Volltextzugriff (PDF)

Abstract 3481: Pharmacokinetics of alofanib and biomarker analysis in patients with advanced gastric cancer: A phase 1b study

Cancer research (Chicago, Ill.), 2022-06, Vol.82 (12_Supplement), p.3481-3481

2022

Volltextzugriff (PDF)

Overall Survival of Patients With ALK -Positive Metastatic Non-Small-Cell Lung Cancer in the Russian Federation: Nationwide Cohort Study

Journal of global oncology, 2019-05, Vol.5 (5), p.1-7

2019

Volltextzugriff (PDF)

BA2-4. Durvalumab + Platinum-Etoposide vs Platinum-Etoposide in 1L Extensive-Stage SCLC : CASPIAN Study

Japanese Journal of Lung Cancer, 2019-11, Vol.59 (6), p.541-541

2019

Volltextzugriff (PDF)

Development of technology for food concentrates of culinary sauces of increased nutritional and biological value

AIMS agriculture and food, 2020-01, Vol.5 (1), p.137-149

2020

Volltextzugriff (PDF)

Economic and statistical analysis of industrial production in the North Caucasian Federal District of the Russian Federation

Nexo (Managua, Nicaragua), 2023-06, Vol.36 (3), p.363-373

2023

Volltextzugriff (PDF)

1 – 25 von 26

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(24)
Mit Volltextzugriff
(23)

Publikationsform

Artikel
(26)

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Impact of Brain Metastases on Treatment Patterns and Outcomes With First-Line Durvalumab Plus Platinum-Etoposide in Extensive-Stage SCLC (CASPIAN): A Brief Report

Overall survival in patients with metastatic renal cell carcinoma in Russia, Kazakhstan, and Belarus: a report from the RENSUR3 registry

Clinical case of long-term use of durvalumab in the treatment of advanced small-cell lung cancer

A phase Ib study of alofanib, an allosteric FGFR2 inhibitor, in patients with advanced or metastatic gastric cancer

The association of access to systemic therapy and overall survival in metastatic bladder cancer in Russia: An analysis of URRU register

Durvalumab ± Tremelimumab + Platinum-Etoposide in Extensive-Stage Small Cell Lung Cancer (CASPIAN): Outcomes by PD-L1 Expression and Tissue Tumor Mutational Burden

Alofanib in subsequent therapy for advanced gastric cancer: Final results from the phase Ib clinical trial

Patient-reported outcomes with first-line durvalumab plus platinum-etoposide versus platinum-etoposide in extensive-stage small-cell lung cancer (CASPIAN): a randomized, controlled, open-label, phase III study

A first-in-human phase 1b study of a novel allosteric extracellular FGFR2 inhibitor alofanib in patients with refractory metastatic gastric cancer

A phase 1b study of the allosteric extracellular FGFR2 inhibitor alofanib in patients with pretreated advanced gastric cancer

Abstract CT113: Preliminary data on a phase 1b, first-in-human study of the allosteric extracellular FGFR2 inhibitor alofanib in patients with refractory metastatic gastric cancer

O11-5 Durvalumab(D) ± tremelimumab(T) + platinum-etoposide(EP) in 1L ES-SCLC: Characterization of long-term benefit in CASPIAN

Elderly patients have limited access to systemic therapy for metastatic renal cell carcinoma (mRCC) and shorter overall survival in Russia, Belarus and Kazakhstan

First-line durvalumab plus platinum-etoposide in extensive-stage (ES)-SCLC (CASPIAN): Impact of brain metastases on treatment patterns and outcomes

Durvalumab ± tremelimumab + platinum-etoposide in first-line extensive-stage SCLC (ES-SCLC): Updated results from the phase III CASPIAN study

Five-year Survival of Patients With Metastatic Renal Cell Carcinoma in the Russian Federation: Results From the RENSUR5 Registry

Five-year overall survival among patients with metastatic renal cell carcinoma: Results of Russian population-based study RENSUR5

Non-interventional study OVATAR final report: Diagnostic and treatment approaches in Russian ovarian cancer population—BRCAm group analysis

Interim analysis of the data of non-interventional study to determine the prevalence of EGFR mutations in advanced NSCLC Russian patients (ORTUS)

Comprehensive analysis of germline and somatic BRCA1/2 mutations in ovarian cancer population: Interim results of OVATAR prospective study

Abstract 3481: Pharmacokinetics of alofanib and biomarker analysis in patients with advanced gastric cancer: A phase 1b study

Overall Survival of Patients With ALK -Positive Metastatic Non-Small-Cell Lung Cancer in the Russian Federation: Nationwide Cohort Study

BA2-4. Durvalumab + Platinum-Etoposide vs Platinum-Etoposide in 1L Extensive-Stage SCLC : CASPIAN Study

Development of technology for food concentrates of culinary sauces of increased nutritional and biological value

Economic and statistical analysis of industrial production in the North Caucasian Federal District of the Russian Federation

Suchergebnisse filtern